Cover Image
市場調查報告書

隱孢子蟲症:開發中產品分析

Cryptosporidiosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 321928
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
隱孢子蟲症:開發中產品分析 Cryptosporidiosis - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 30 Pages
簡介

由於根據稱作隱孢子蟲症,隱孢子蟲的微小的寄生蟲引起的急性的疾病,症狀水先生的腹瀉,脫水,食慾不振,體重減少,發熱,噁心和嘔吐等舉出(舉行)。發病要素被污染了的水,及照顧動物時感染。

本報告提供隱孢子蟲症 對於的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

隱孢子蟲症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

隱孢子蟲症:企業開發中的治療藥

隱孢子蟲症:大學/機關研究中的治療藥

隱孢子蟲症:開發中產品概況

  • 初期階段的產品

隱孢子蟲症:企業開發中的產品

隱孢子蟲症:大學/機關研究中的產品

隱孢子蟲症的治療藥的開發企業

  • Dafra Pharma International Ltd.
  • ioGenetics, Inc.
  • Romark Laboratories, L.C.

隱孢子蟲症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

隱孢子蟲症:暫停中的計劃

隱孢子蟲症:開發中止的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9894IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H2 2017, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.

Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cryptosporidiosis - Overview
    • Cryptosporidiosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cryptosporidiosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cryptosporidiosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • ioGenetics Inc
    • Novartis AG
    • Romark Laboratories LC
  • Cryptosporidiosis - Drug Profiles
    • DBAF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPLAJ-1317 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDU-731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-131 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RM-5038 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cryptosporidiosis - Dormant Projects
  • Cryptosporidiosis - Discontinued Products
  • Cryptosporidiosis - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cryptosporidiosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cryptosporidiosis - Pipeline by AbbVie Inc, H2 2017
  • Cryptosporidiosis - Pipeline by ioGenetics Inc, H2 2017
  • Cryptosporidiosis - Pipeline by Novartis AG, H2 2017
  • Cryptosporidiosis - Pipeline by Romark Laboratories LC, H2 2017
  • Cryptosporidiosis - Dormant Projects, H2 2017
  • Cryptosporidiosis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cryptosporidiosis, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top